How a gut-lining antioxidant (GPx1) affects intestinal health
Epithelial specific roles for GPx1 in the intestinal microenvironment
Researchers are looking at whether removing a common antioxidant enzyme called GPx1 from gut lining cells changes how the intestine repairs itself during inflammation, which could matter for people with inflammatory bowel disease.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11301821 on NIH RePORTER |
What this research studies
The team made a new mouse model that lets them delete GPx1 only in intestinal epithelial (lining) cells and will use that model alongside lab-grown intestinal organoids and a chemical colitis model to study outcomes. They will compare tissue repair, stem cell activity, and cell proliferation when epithelial GPx1 is missing versus normal. The work builds on earlier whole-body GPx1 knockout results that unexpectedly protected mice from colitis and aims to see if the protection is driven by the lining cells themselves. Findings will clarify whether targeting epithelial GPx1-related pathways could change how the gut heals after injury.
Who could benefit from this research
Good fit: This research is most relevant to people with inflammatory bowel diseases such as ulcerative colitis or Crohn’s disease who want to learn about potential new pathways for healing the intestine.
Not a fit: People without intestinal inflammation or conditions affecting the gut are unlikely to gain direct benefit from this specific laboratory-focused work.
Why it matters
Potential benefit: If successful, this could point to new ways to promote intestinal repair and suggest targets for therapies to help people with IBD.
How similar studies have performed: Previous whole-body GPx1 knockout mouse studies showed unexpected protection from chemically induced colitis, but testing epithelial-specific GPx1 effects in a new floxed mouse model is a novel step.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Short, Sarah Palmer — University of Iowa
- Study coordinator: Short, Sarah Palmer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.